Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Levocarnitine Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.68 |
| ▸ | GMNN | O75496 | 3/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.68 |
| ▸ | BLM | P54132 | 2/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levocarnitine Propionate SCHEMBL8617433 | 1.00 | MEN1 (0.70) | MEN1KMT2ACYP2C19RECQLLMNA | |
| Levocarnitine Propionate SCHEMBL1650830 | 1.00 | MEN1 (0.70) | MEN1KMT2ACYP2C19RECQLLMNA | |
| Levocarnitine Propionate SCHEMBL12015471 | 0.98 | MEN1 (0.72) | MEN1KMT2ACYP2C19RECQLLMNA | |
| Levocarnitine Propionate SCHEMBL12137155 | 0.98 | MEN1 (0.72) | MEN1KMT2ACYP2C19RECQLLMNA | |
| Levocarnitine Propionate SCHEMBL16806474 | 0.98 | MEN1 (0.72) | MEN1KMT2ACYP2C19RECQLLMNA | |
| Levocarnitine Propionate SCHEMBL27542240 | 0.96 | MEN1 (0.70) | MEN1KMT2ACYP2C19RECQLLMNA | |
| Levocarnitine Propionate SCHEMBL28746108 | 0.96 | MEN1 (0.70) | MEN1KMT2ACYP2C19RECQLLMNA | |
| Levocarnitine Propionate SCHEMBL27542239 | 0.96 | MEN1 (0.70) | MEN1KMT2ACYP2C19RECQLLMNA | |
| Levocarnitine Propionate SCHEMBL3005247 | 0.96 | MEN1 (0.70) | MEN1KMT2ACYP2C19RECQLLMNA | |
| Levocarnitine Propionate SCHEMBL27522147 | 0.96 | MEN1 (0.70) | MEN1KMT2ACYP2C19RECQLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4708655-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| EP-1257524-B1 | A PROCESS FOR THE PREPARATION OF SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINE WITH MUCIC ACID | SIGMA TAU IND FARMACEUTI (IT) | 2005-11-02 | — | — | EP | claimed |
| US-6693215-B2 | TREATING CARNITINE CHLORIDE WITH AN ION EXCHANGER TO FORM AN INNER SALT IN AQUEOUS SOLUTION BEFORE REACTING WITH MUCIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-02-17 | — | — | US | claimed |
| US-20030130539-A1 | Process for the preparation of salts of l-carnitine and alkanoyl l-carnitine with mucic acid | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-07-10 | — | — | US | claimed |
| EP-1257524-A1 | A PROCESS FOR THE PREPARATION OF SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINE WITH MUCIC ACID | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-11-20 | — | — | EP | claimed |
| WO-2001058850-A1 | A PROCESS FOR THE PREPARATION OF SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINE WITH MUCIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-08-16 | — | — | WO | claimed |
| US-6217898-B1 | ANTICHOLESTEROL AGENTS | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2001-04-17 | — | — | US | claimed |
| JP-63267716-A | — | — | None | — | — | JP | disclosed |
| US-7858820-B2 | Solid compositions suitable for oral administration containing non-hygroscopic salts of L-carnitine and the alkanoyl L-carnitines with taurine chloride and glycine chloride | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-28 | — | — | US | disclosed |
| EP-1330428-B1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND THE ALKANOYL L-CARNITINES WITH TAURINE CHLORIDE | SIGMA TAU IND FARMACEUTI (IT) | 2005-12-14 | — | — | EP | disclosed |
| EP-1257524-B1 | A PROCESS FOR THE PREPARATION OF SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINE WITH MUCIC ACID | SIGMA TAU IND FARMACEUTI (IT) | 2005-11-02 | — | — | EP | disclosed |
| EP-1202956-B1 | THERAPEUTICALLY AND/OR NUTRITIONALLY ENHANCED DERIVATIVES OF ACTIVE INGREDIENTS AND ORALLY ADMINISTRABLE COMPOSITIONS CONTAINING SAME | SIGMA TAU IND FARMACEUTI (IT) | 2004-05-19 | — | — | EP | disclosed |
| US-6703042-B1 | STABLE, NON-HYGROSCOPIC; NUTRITIONAL SUPPLEMENTS | SIGMA-TAU INDUSTRIES FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-03-09 | — | — | US | disclosed |
| EP-0514359-A2 | Alkanoyl L-carnitine amides with aminoacids and pharmaceutical compositions containing same, for promoting regeneration of the nervous tissue, inhibiting neuronal degeneration, enhancing the processes of learning and memory, and for the treatment of coma | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-11-19 | — | — | EP | disclosed |
| EP-0514357-A1 | Use of esters of acyl L-carnitines with gamma-hydroxybutyric acid for producing pharmaceutical compositions for the treatment of hepatopathies | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-11-19 | — | — | EP | disclosed |
| EP-0442850-A1 | Esters of acyl L-carnitines with gamma-hydroxybutyric acid and pharmaceutical compositions containing them for inhibiting neuronal degeneration and for the treatment of coma | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1991-08-21 | — | — | EP | disclosed |
| JP-S63267716-A | REMEDY FOR UREA CYCLE DYSBOLISM | EARTH CHEM CORP LTD | 1988-11-04 | — | — | JP | disclosed |
| EP-0150688-B1 | SALTS OF L-CARNITINE AND ALKANOYL L-CARNITINES AND PROCESS FOR PREPARING SAME | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1987-04-22 | — | — | EP | disclosed |
| US-4602039-A | HYDROPHOPIC;BIOLOGICAL INJECTIONS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1986-07-22 | — | — | US | disclosed |
| EP-0150688-A1 | Salts of L-carnitine and alkanoyl L-carnitines and process for preparing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130539-A1 | Process for the preparation of salts of l-carnitine and alkanoyl l-carnitine with mucic acid | CRAT, SLC25A20, MUC1 | MEN1 603/4885KMT2A 1432/4885CYP2C19 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.